GeoVax Labs (GOVX) Return on Capital Employed (2011 - 2026)
GeoVax Labs (GOVX) posted quarterly Return on Capital Employed of 743.79% for Q2 2026, down 29395.0% year-over-year from N/an in Q2 2025, and down 58.11% quarter-over-quarter from 470.43% in Q4 2025.
GeoVax Labs (GOVX) Return on Capital Employed (2011 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Return on Capital Employed for 16 consecutive years, with 743.79% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Capital Employed fell 29395.0% year-over-year to 743.79%; the TTM figure through Jun 2026 stood at 743.79% (down 29395.0% YoY), while the FY2025 annual figure was 407.35%, up 4068.0% from the prior year.
- Return on Capital Employed eased to 743.79% in Q2 2026 per GOVX's latest filing, from 470.43% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1017.26% in Q2 2024 and bottomed at 939.92% in Q1 2024.
- Historically, Return on Capital Employed has averaged 264.66% across 5 years, with a median of 289.98% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 111512 bps — and 2025, when it sank 146710 bps.
- GeoVax Labs' Return on Capital Employed stood at 46.43% in 2022, then tumbled by 524 bps to 289.98% in 2023, then sank by 33 bps to 385.26% in 2024, then fell by 22 bps to 470.43% in 2025, then plunged by 58 bps to 743.79% in 2026.
- Business Quant data shows GOVX's Return on Capital Employed at 743.79% in Q2 2026, 470.43% in Q4 2025, and 605.73% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | -743.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -743.79% |
| Dec 31, 2025 | -470.43% |
| Sep 30, 2025 | -605.73% |
| Jun 30, 2025 | -449.84% |
| Mar 31, 2025 | -376.05% |
| Dec 31, 2024 | -385.26% |
| Sep 30, 2024 | -490.32% |
| Jun 30, 2024 | 1,017.26% |
| Mar 31, 2024 | -939.92% |
| Dec 31, 2023 | -289.98% |
| Sep 30, 2023 | -209.88% |
| Jun 30, 2023 | -97.86% |
| Mar 31, 2023 | -63.90% |
| Dec 31, 2022 | -46.43% |
| Sep 30, 2022 | -71.94% |
| Jun 30, 2022 | -93.94% |
| Mar 31, 2022 | -181.16% |
| Dec 31, 2021 | -194.60% |
| Sep 30, 2021 | -33.82% |
| Jun 30, 2021 | -23.99% |